PRODUCT MONOGRAPH. HAVRIX hepatitis A vaccine, inactivated. Suspension This leaflet is part III of a three-part “Product Monograph”. HAVRIX, hepatitis A vaccine, is a sterile suspension containing formaldehyde – has resulted from the administration of any vaccine product. Havrix (Hepatitis A Vaccine, Inactivated) is a noninfectious hepatitis A vaccine .. NDC Package of 1 Prefilled Disposable Tip-Lokâ Syringe.

Author: Takree Shashura
Country: Romania
Language: English (Spanish)
Genre: Sex
Published (Last): 9 February 2014
Pages: 236
PDF File Size: 4.80 Mb
ePub File Size: 3.55 Mb
ISBN: 875-4-48679-560-3
Downloads: 94257
Price: Free* [*Free Regsitration Required]
Uploader: Yotilar

Long term follow-up studies will determine the necessity for booster doses of HAV. Havrix is available in vials and 2 types of prefilled syringes. Moderate Administer all non-live vaccines at least 2 weeks before ocrelizumab initiation, whenever possible. The vaccine should be used as supplied; no dilution or reconstitution is necessary.

Related Drug Information Drug Summary. Intravenous administration, subcutaneous administration. Angioedema, erythema multiforme, hyperhidrosis.

Additionally, it may not prevent infection in individuals who do not achieve protective antibody titers although the lowest titer needed to confer protection has not been determined. However, as with all inactivated viral vaccines, the risks to the fetus are considered negligible.

In a prospective, open-label, multicenter study, 1, children were enrolled into one of 5 groups:. Patients vaccinated with hepatitis A vaccine, inactivated within 2 weeks before starting immunosuppressive therapy or while receiving immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored.

To view content sources and attributions, please refer to our editorial policy. Immunization against hepatitis A virus in persons at risk; products utilize inactivated whole virus propagated in MRC5 human diploid cells. We comply with the HONcode standard for trustworthy health information – verify here. Find out more here. However, the lowest titer needed to confer protection has not been determined. A decision must be made whether to discontinue breast-feeding or to abstain from vaccination taking into account the benefit of breast feeding for the child and the benefit of vaccination for the woman.


Havrix should be given to a pregnant woman only if clearly needed. Havrix should not be administered in the gluteal region; such injections may result in suboptimal response. The duration of immunity following a complete schedule of immunization with Havrix has not been established. Store refrigerated at 2—8 degrees C 36 to 46 degrees F ; do not freeze.

Hepatitis A vaccine, inactivated is only indicated for intramuscular administration; do not give via intravenous administration, subcutaneous administration, or intradermal administration. Patients who develop symptoms suggestive of hypersensitivity should not receive further injections of the vaccine.

This suspension is purified through ultrafiltration and gel permeation chromatography procedures.

Havrix Monodose Vaccine

Shake vial or syringe well before withdrawal and use. Group 1 Havrix coadministered with pneumococcal 7-valent conjugate vaccine Wyeth Pharmaceuticals Inc.

To bookmark a medicine you must sign up and log in. Infants born to mothers exposed to pckage during pregnancy may receive non-live vaccines as indicated before B-cell recovery; however, consider assessing the immune response to the vaccine. Immune globulin is preferred, although 1 mL IM of the vaccine may be used if immune globulin cannot inssrt obtained.

Ocrelizumab may interfere with the effectiveness of non-live virus vaccines. Inseft GMTs obtained following a single dose of Havrix are at least several times higher than that expected following receipt of immune globulin.

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records.

Havrix (hepatitis A vaccine) dose, indications, adverse effects, interactions from

It is not known whether Havrix is excreted in human milk. In addition there may be other groups at risk or specific circumstances such as an outbreak of hepatitis A infection when immunisation should be given. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids used in greater than physiologic dosesmay reduce the immune response to Havrix.


The association of these events with vaccination is unknown. By continuing to browse the site you are agreeing to our policy on the use of cookies.

Enter medicine name or company Start typing to retrieve search packabe. For primary immunization Havrix or Vaqta. These studies indicated that administration of a single dose of Havrix contributed to termination of the outbreaks. No studies on the effects of Havrix Monodose on the ability to drive and use machines have been performed. Adults older than 40 years. This response lasts for several months, but during convalescence antibodies of the IgG class become dominant.

A separate syringe and needle should be used for each person receiving hepatitis A vaccine, inactivated. ACIP recommends that pwckage receiving any vaccination during immunosuppressive inert or in the 2 weeks prior to starting therapy should be considered unimmunized and should be revaccinated a minimum of 3 months after discontinuation of therapy. In order to ensure long term protection, a booster dose should be given between 6 and 12 months after the primary dose.

Havrix – FDA prescribing information, side effects and uses

All events were reported as recovered or recovering by the end of the study. The response to this booster knsert is vigorous and increases the protection time against hepatitis A.

Provide the Vaccine Information Statements from the manufacturer to the recipient or guardian before each immunization. A similar effect could be observed with Havrix Monodose.

PDR Search

Immunogenicity of Havrix was studied in subjects with chronic liver disease of various etiologies. The vaccine should be given only if the potential benefits clearly outweigh the risk of administration. If either of these conditions exists, the vaccine should not be administered.